Factors associated with relapse in adult patients discharged from the emergency department following acute asthma: a systematic review

Jesse Hill,1,2 Nicholas Arrotta,2,3 Cristina Villa-Roel,1,2,4 Liz Dennett,5 Brian H Rowe2,4,6

ABSTRACT

A significant proportion of patients discharged from the emergency department (ED) with asthma exacerbations will relapse within 4 weeks. This systematic review summarises the evidence regarding relapses and factors associated with relapse in adult patients discharged from EDs after being treated for acute asthma. Following a registered protocol, comprehensive literature searches were conducted. Studies tracking outcomes for adults after ED management and discharge were included if they involved adjusted analyses. Methodological quality was assessed using the Newcastle–Ottawa Scale (NOS) and the Risk of Bias (RoB) Tool. Results were summarised using medians and IQRs or mean and SD, as appropriate. 178 articles underwent full-text review and 10 studies, of various methodologies, involving 32,923 patients were included. The majority of the studies were of high quality according to NOS and RoB Tool. Relapse proportions were 8±3%, 12±4% and 14±6% at 1, 2 and 4 weeks, respectively. Female sex was the most commonly reported and statistically significant factor associated with an increased risk of relapse within 4 weeks of ED discharge for acute asthma. Other factors significantly associated with relapse were past healthcare usage and previous inhaled corticosteroids (ICS) usage. A median of 17% of patients who are discharged from the ED will relapse within the first 4 weeks. Factors such as female sex, past healthcare usage and ICS use at presentation were commonly and significantly associated with relapse occurrence. Identifying patients with these features could provide clinicians with guidance during their ED discharge decision-making.

INTRODUCTION

Asthma affects over 17.5 million adults in North America and its prevalence continues to rise, as evidenced by the 12.3% relative increase from 2001 (7.3%) to 2009 (8.2%). Worldwide, asthma prevalence ranges from low (underdeveloped countries) to high (developed countries). Asthma is predominantly a chronic disease that can be controlled with appropriate pharmacological and non-pharmacological interventions; however, exacerbations do not always respond to standard or additional treatment options, leading to urgent visits to health providers, admissions to hospital and, in severe and rare cases, death. In the USA, patients with exacerbations had significantly higher asthma-related healthcare costs: $1740 over 1 year compared with $847 for asthmatics without exacerbations. While patients with acute asthma often seek care in the emergency department (ED), most are successfully treated and subsequently discharged; only 6–12% of adult patients presenting to the ED with an exacerbation of asthma will be admitted. The understanding and management of acute asthma have advanced considerably in recent years. Current evidence-based guidelines (National Asthma Education and Prevention Plan (NAEPP), Global Initiative for Asthma (GINA), and Canadian Thoracic Society (CTS)) suggest that early treatment with short-acting β2-agonists, inhaled short-acting anticholinergic agents and systemic corticosteroids (SCS) will reduce hospitalisations. On ED discharge, SCS are recommended and further studies suggest that prescribing inhaled corticosteroids (ICS) at discharge can reduce relapse following discharge at least in adult patients. ICS in combination with long-acting β2-agonists (ICS/LABA) are more effective than ICS monotherapy in patients with persistent asthma, with the number needed to treat of 19 to prevent one exacerbation. On the other hand, the impact of non-pharmacological interventions (ie, ED-based educational strategies) on relapses remains unclear.

While considerable improvement in the management of acute asthma should lead to...
better outcomes over time, practice variation does exist and many patients presenting to EDs do not always receive evidence-based treatment.\textsuperscript{13} Moreover, what works in certain settings may not be applicable to others. Despite the dissemination of effective interventions for the prevention of relapses after asthma exacerbations, these outcomes still occur, affect the quality of life\textsuperscript{21} of patients with asthma and represent significant costs to the healthcare system.\textsuperscript{5}

A number of studies have examined factors associated with relapse outcomes in adults after ED discharge.\textsuperscript{22–26} Notwithstanding this research, there remains a relative paucity of literature attempting to compile the existing information to influence management. The objective of this study was to summarise the evidence regarding relapses and factors associated with increased relapse in patients discharged from EDs after being treated for asthma exacerbations.

### METHODS

#### Protocol

A study protocol was developed a priori to define the objectives, search strategy, eligibility criteria, outcomes of interest, the process for abstracting and synthesising information from eligible studies, and the methods for data analysis. The systematic review conforms to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with International prospective register of systematic reviews (PROSPERO) (CRD42015023844). No ethics approval was required.

#### Literature search

Comprehensive searches of seven electronic databases (Medline, EMBASE, Cochrane Library, CINAHL, SCOPUS, LILAC, and ProQuest Dissertations and Theses) were conducted from their inception to June 2015. The search strategy was designed by a health sciences librarian (LD) and comprised controlled vocabulary and keywords. The search used a slightly modified version of an ‘emergency room’ search filter\textsuperscript{27} (see online supplementary appendix A; complete search strategy is available on request).

References were manually selected from the first 10 pages of Google Scholar. In addition, proceedings from important Canadian Association of Emergency Physicians (CAEP) and US Society for Academic Emergency Medicine (SAEM) conferences held between 2005 and 2015 that involved research presentations were hand-searched. No limits were applied on the basis of date, study design, language or publication status.

#### Study selection

The review included studies assessing the proportion of adult patients (or adults and children with ≥80% of the study population being ≥17 years of age) relapsing after receiving treatment in the ED for an asthma exacerbation. Relapse and variables significantly associated with relapse after multivariable modelling were the primary outcomes presented in this review. To be included as factors associated with relapse, studies must have conducted adjusted analyses. Relapse was defined as an urgent visit to any ED, clinic or physician office for worsening asthma symptoms within 4 weeks of the initial ED visit. Secondary outcomes included time between ED discharge and relapse, and medical management received in the ED.

Two reviewers (JH, NA) independently screened the titles and abstracts of studies identified by the literature search. Articles initially deemed relevant and those whose abstracts and titles provided insufficient information were retrieved and independently reviewed (JH, NA) to determine study eligibility. Disagreements were discussed and resolved with a third party (CVR).

#### Data extraction and quality assessment

Information on patients, methods, interventions and outcomes was extracted from the original reports onto standardised data collection forms independently by two authors (JH, NA). Information was cross-referenced to ensure accuracy. If necessary, authors were contacted to clarify information or provide unpublished data.

#### Assessment of study quality

Two reviewers (JH, NA) independently evaluated each of the included studies using the Newcastle–Ottawa Scale (NOS) for observational studies and the Cochrane Risk of Bias Tool (RoB), a quality assessment tool used to assess controlled clinical trials (CCT) for risk of bias. Any discrepancies were discussed with a third party (CVR). Information on study quality will help authors evaluate the validity of the findings.

#### Data synthesis and statistical analysis

Characteristics of the included studies were summarised using descriptive statistics (eg, numbers with proportions for dichotomous variables and means with standard deviations (±SD) or medians with interquartile ranges (IQR) for continuous variables). An evidence table was constructed to report information on each article’s source, year of publication, country of origin, study design, sample size and outcomes. Analyses were focused on the proportion of relapses; a subgroup analysis by the end of data collection (year) was completed. Inter-rater agreement between the two reviewers evaluating study quality using the NOS was measured using the κ statistic. Effect estimates from individual studies were presented as adjusted ORs (aORs) with 95% CIs when possible. Owing to the variations in models used to generate aORs and in the factors reported, results were not pooled in a traditional meta-analysis. Finally, factors associated with relapse at a statistically significant level (p<0.05) were summarised in a table. Figures were generated using GraphPad Prism V.6.07 for Windows (GraphPad Software, La Jolla, California, USA).
RESULTS

Search results

After combining the results of the electronic search strategy with the grey literature, removing duplicates, screening for titles and abstracts, and reviewing full-text articles, 10 studies were included in the review (figure 1). The most common reason for exclusion was a lack of multivariate analysis (n=55; including 19 randomised controlled trials (RCTs)), followed by studies that were not primary research (n=48). Studies which did not examine relapse (n=22) and those which had a partially or wholly inpatient population (n=20) were also excluded. A minority of studies (n=23) were excluded for various other reasons, such as the involvement of paediatric populations, or patient presentation to the ED was not due to acute asthma. A full list of excluded studies is available on request.

Study characteristics

Five prospective cohort studies,22–24 26 28 two retrospective cohort studies,29 30 two administrative data analyses31 32 and one RCT33 were included (table 1). Apart from one study,30 all included studies were conducted in North America.22–24 26 28 29 31–33 Similarly, aside from one abstract, all other included studies were published peer-reviewed articles.29 One study performed its multivariate analysis based on 8-week relapse proportions.24 Demographic characteristics of included studies are displayed in table 2. Note that ED management was left to the discretion of the treating physician in all studies but one,24 which outlined a specific protocol. The definition of relapse was commonly given as some variant of ‘any urgent medical treatment for asthma, regardless of location of care’, except for two studies30 32 that restricted their relapses to those presenting back to the ED.

Quality assessment

All included observational studies had a relatively low risk of bias according to the NOS. Two studies26 28 scored seven out of eight possible points because their loss to follow-up was >20%. All the remaining studies scored the full eight points (k=0.73). The included RCT had low risk of bias according to the RoB Tool.

Primary outcomes

Relapse proportions

One RCT35 and seven observational studies22–24 26 28 30 32 33 reported the proportion of patients experiencing relapse after management and discharge for acute asthma. The authors of the two29 31 studies that failed to report their relapse proportions were contacted; however, in both cases, additional information was not obtained. Relapse proportions were recorded at 1 week,22–24 26 32 33 2 weeks22–24 26 28 32 33 and 4 weeks.23 24 30 The relapse proportion at 2 weeks ranged from 4%31 to 17%.26 When 2-week and 4-week relapse proportions were examined based on the studies’ last year of data collection, there were slightly lower relapse rates in recent years (figure 2). Six studies tracked relapse proportions at multiple postdischarge durations.22–24 26 32 33 All six studies had the greatest proportion of relapses occurring within the first week, with a median of 61% (IQR: 50–68) of all relapses occurring during week one. After this early peak, relapse proportions appear to increase at a relatively linear rate.

Figure 1  PRISMA flow diagram illustrating the overview of the systematic literature search.

1453 records identified through electronic database searching

703 duplicates removed

793 screened by title and abstract

615 studies excluded

178 articles underwent full text screen to assess for eligibility

168 studies failed to meet the inclusion criteria*

Attempted to contact authors for additional information

10 studies included in final analysis

43 additional records identified through manual abstract searching of CCM and SAEM conference records

*Top 3 reasons for exclusion:

1. Lacking multivariate analysis (n=55)
2. Not primary research (n=48)
3. Subacute relapse rates not examined (n=22)
between weeks 1 and 4 (figure 3). Median relapses were 8% at 1 week, 14% at 2 weeks, and 17% at 4 weeks (figure 3).

Factors significantly associated with relapse

Although 19 RCT studies underwent a full-text review, only one paper was included. There were two studies which reported performing multivariate analyses, but the results were not presented. In the included RCT, there were three factors identified as significant on multivariate analysis: ICS use prior to ED presentation, prior intubation and female sex. The strongest association identified in the RCT was female sex (HR=7.2; 95% CI 2.3 to 23.1).

Factors commonly and significantly associated with relapse occurrence within 4 weeks of ED discharge in observational studies included: patient sex, previous healthcare usage, symptom duration and ICS usage at ED presentation. The most commonly investigated variable was female sex; from models reported in six studies, five reported a significant finding with aOR ranging from 1.17 (95% CI 1.03 to 1.34) to 7.2 (95% CI 2.3 to 23.1) (figure 4).

Healthcare usage included subcategories (table 3) for ED asthma visits such as: visits that occurred in the past 6 months, 1 year, and 2 years, past urgent clinic visits for asthma and prior hospitalisations for asthma. Severity at ED presentation was assessed using the Canadian Triage and Acuity Scale (CTAS) score of one. Symptom duration was assessed either directly by the Canadian Triage and Acuity Scale (CTAS) score of the ED asthma visit, 22 or indirectly by asking how long they had been experiencing difficulties with activities or work. 24

Secondary outcomes

Time between ED discharge and relapse

One study reported that the median time to relapse was 9 days (IQR: 3–19), however, no other studies reported this outcome.

Medical management

Four studies reported that the proportion of patients arriving with a recent history of SCS use ranged from 2% to 23%. Similarly, five studies tracked those patients receiving SCS after ED discharge, as ranging from 63% to 100%. Proportions of patients prescribed ICS at ED presentation, and those prescribed ICS at discharge varied widely among studies with ranges of 35–82% and 29–100%, respectively. ICS/LABA usage at presentation was reported by three studies and was relatively consistent with a range from 32–33%. Short-acting β2-agonist use before presentation was much more uniform (82–87%).

DISCUSSION

This comprehensive systematic review identified 10 studies involving 32,923 patients that performed multivariate analysis to investigate factors associated with relapse after treatment for adult patients seen with acute asthma in the ED setting. Quality assessment showed that all included studies were of high methodological quality, which strengthens the validity of these results. Given the variations in models used to generate aORs and in the factors reported, results were not pooled in a traditional meta-analysis. Overall, there is strong

Table 1 Descriptive characteristics of studies selected for inclusion in the review

<table>
<thead>
<tr>
<th>Author</th>
<th>Year of publication</th>
<th>Country</th>
<th>Study design</th>
<th>Study period</th>
<th>Sample size</th>
<th>Relapse proportion (at 2 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rowe 33</td>
<td>2007</td>
<td>Canada</td>
<td>Randomised</td>
<td>–</td>
<td>137</td>
<td>12.40%</td>
</tr>
<tr>
<td>McCarren 24</td>
<td>1998</td>
<td>USA</td>
<td>Prospective cohort</td>
<td>1992–1995</td>
<td>284</td>
<td>10%</td>
</tr>
<tr>
<td>Emerman 26</td>
<td>1999</td>
<td>USA</td>
<td>Prospective cohort</td>
<td>1996–1997</td>
<td>641</td>
<td>17%</td>
</tr>
<tr>
<td>Singh 29</td>
<td>1999</td>
<td>USA</td>
<td>Prospective cohort</td>
<td>1996–1997</td>
<td>1228</td>
<td>15.80%</td>
</tr>
<tr>
<td>Rowe 23</td>
<td>2008</td>
<td>Canada</td>
<td>Prospective cohort</td>
<td>2004–2005</td>
<td>695</td>
<td>13.90%</td>
</tr>
<tr>
<td>Rowe 23</td>
<td>2015</td>
<td>Canada</td>
<td>Prospective cohort</td>
<td>2003–2007</td>
<td>807</td>
<td>14%</td>
</tr>
<tr>
<td>Lin 30</td>
<td>2009</td>
<td>Canada</td>
<td>Retrospective cohort</td>
<td>2006–2007</td>
<td>257</td>
<td>–</td>
</tr>
<tr>
<td>Prabakaran 30</td>
<td>2013</td>
<td>Singapore</td>
<td>Retrospective cohort</td>
<td>2008–2009</td>
<td>1303</td>
<td>7.4% (4 week)</td>
</tr>
<tr>
<td>Withy 32</td>
<td>2008</td>
<td>USA</td>
<td>Administrative database</td>
<td>1999–2004</td>
<td>4318</td>
<td>4%</td>
</tr>
<tr>
<td>Study</td>
<td>Age (mean)</td>
<td>Female (%)</td>
<td>COPD status</td>
<td>Discharge medication</td>
<td>Race (largest proportion)</td>
<td>Current smoking (%)</td>
</tr>
<tr>
<td>----------------</td>
<td>------------</td>
<td>------------</td>
<td>-------------</td>
<td>----------------------</td>
<td>---------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Rowe (2007)</td>
<td>30±10</td>
<td>59</td>
<td>NA</td>
<td>Prednisone, β-agonist, ICS ± LABA</td>
<td>NA</td>
<td>39</td>
</tr>
<tr>
<td>McCarren (2008)</td>
<td>35±10</td>
<td>40</td>
<td>Excluded</td>
<td>9–11 days of prednisone, theophylline, steroid inhaler</td>
<td>87% black</td>
<td>37</td>
</tr>
<tr>
<td>Emerman (2008)</td>
<td>34±10</td>
<td>69</td>
<td>Excluded</td>
<td>5–7 days of prednisone + EP discretion</td>
<td>49% black</td>
<td>30</td>
</tr>
<tr>
<td>Singh (2015)</td>
<td>36±10</td>
<td>64</td>
<td>3%</td>
<td>67% received steroids</td>
<td>54% black</td>
<td>35</td>
</tr>
<tr>
<td>Rowe (2015)</td>
<td>29±10</td>
<td>64</td>
<td>Excluded</td>
<td>5–7 days of prednisone + EP discretion</td>
<td>87% white</td>
<td>39</td>
</tr>
<tr>
<td>Rowe (2015)</td>
<td>30 (24–39)*</td>
<td>58</td>
<td>Excluded</td>
<td>5–7 days of prednisone + EP discretion</td>
<td>85% white</td>
<td>33</td>
</tr>
<tr>
<td>Lin (2015)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Prabhakaran</td>
<td>36±16</td>
<td>48</td>
<td>Excluded</td>
<td>± prednisolone (79%), ICS</td>
<td>37% Chinese</td>
<td>NA</td>
</tr>
<tr>
<td>Babergenova</td>
<td>NA</td>
<td>62</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Withy (2015)</td>
<td>NA</td>
<td>54</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Median (IQR).
COPD, chronic obstructive pulmonary disease; EP, emergency physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; NA, not available.
evidence that women and patients on pre-existing ICS therapy are more likely to relapse, and perhaps should be managed more aggressively.

Relapse proportions were notably high within the first week in most of the studies which reinforces the need for primary care providers to see patients early after discharge to reassess response to therapy, adjust management and provide additional recommendations. Apart from two studies, relapses were relatively consistent across the included studies: one that reported relapse proportions of 4% at 2 weeks and another that reported 7.4% at 4 weeks. These two studies restricted their outcomes to patients relapsing to EDs and that may have influenced the estimates; all other studies provided patient-reported relapse outcomes involving multiple potential treatment location. In both studies, a large number (44.8% and 46.0%, respectively) of patients had outpatient follow-up arranged prior to discharge to address asthma symptoms, and this is a possible contributor to the significantly reduced proportion of patients relapsing. The author of the second study (based in Singapore and the only study included in this review that originated outside North America) acknowledged that the reported relapse proportions were lower than expected potentially due to differences in healthcare delivery relative to North America. One such difference is a higher availability of after-hours, or 24-hour, primary care. Given the relative recency of these two studies, they are potentially overstating the recent relapse reduction shown in figure 2; despite this, there is some evidence that the number of patients receiving guideline-recommended care in EDs has been increasing over recent years, leading to improved outcomes.

It is important to highlight the large number of relapses occurring within the first few days after ED discharge. Nearly two-thirds of patients experiencing relapse do so within the first week and this appears to be an area where improved ED management, and perhaps strategies to prompt primary care follow-up, could improve outcomes.

Many of the factors significantly associated with relapse risk on multivariate analysis make intuitive sense. Female sex is a predisposing factor for severe asthma and women have been shown to perceive symptoms differently, so it is perhaps not surprising that this review finds that female sex was also associated with more frequent relapses following ED visits for acute asthma. Logic predicts that patients with past tendencies to use the ED will not hesitate to return; likewise, patients who are experiencing unrelenting symptoms over a longer duration may be struggling with self-management of their asthma, or have more severe baseline disease, and may need urgent care. Indeed, lack of symptom improvement has been identified as a common cause for patients with asthma to seek urgent care. Although infrequently examined by these studies, medication cost and patient insurance certainly impact treatment efficacy, especially when we consider that up to 37% of patients will not fill their prescriptions after an asthma exacerbation. It was encouraging that results were directionally concurrent; in other words, there were no factors associated with relapse that were found to reduce relapse among the included studies.

Studies discussing asthma relapse are common in the medical literature; however, no similar systematic reviews were identified in our searches. In addition, while most guidelines do make mention of factors associated with relapse, the vast majority are not evidence-based and nor do they provide recommendations on how to use these factors in practice. For example, the most recent guideline from the GINA focused on medical management to prevent asthma relapse, provided no summary of factors associated with relapse, and failed to guide clinicians regarding which high-risk patients to target. In a similar vein, the National Review on Asthma Deaths (NRAD) in 2015 identified that 10% of asthma deaths in the UK occur within 28 days of discharge from the ED. The authors state that there is a need for health professionals to ‘be aware of the factors that increase the risk of asthma attacks’, without explicitly stating what those factors are.

Factors which could practically be screened to provide the most benefit would include female sex, previous ICS...
usage and healthcare resource usage. Identifying patients with these traits and targeting them for more explicit discharge planning and rigorous outpatient follow-up might mitigate the severity and frequency of relapses. Options might include the identification of care gaps that may influence their asthma attacks (ie, improper inhaler techniques, non-adherence to medication, lack of education), stepping up their preventer medication (ie, adding ICS to those ICS naïve at presentation or switching from ICS to ICS/LABA), providing the medications in the ED rather than the prescriptions or directing strategies from the ED to ensure that patients have close follow-up with a primary care provider for monitoring of symptoms, adjustment on medication and consideration of referrals.

STRENGTHS AND LIMITATIONS

There are several potential limitations to this review that require discussion. First, high-quality evidence in this field is limited and this review included a variety of prospective designs (eg, RCTs and cohorts), which was an important a priori decision. To be reported in the factors associated with relapses, all prospective studies needed to report an adjusted analysis. Second, data collected from patient interviews may be subject to recall bias. With a few exceptions, data were collected using slightly different interview questions, necessitating some grouping based on author discretion. In addition, differential loss to follow-up or incomplete outcome data in the included studies may have introduced attrition bias. Third, owing to the relatively small number of included studies and overall small sample size, we were unable to formally assess the potential for publication bias; however, comprehensive searches of grey and published literature were performed without restrictions on language, dates or publication status, so it is unlikely

Table 3  Factors significantly (p<0.05) associated, on multivariate analysis, with asthma relapse within 4 weeks of ED treatment (✓), factors studied but not found to be significant (Ø) and factors not assessed (NA)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>✓</td>
<td>NA</td>
<td>Ø</td>
<td>✓</td>
<td>✓</td>
<td>NA</td>
<td>NA</td>
<td>✓ (1.23, 1.10 to 1.37)</td>
<td>✓ (1.17, 1.03 to 1.34)</td>
</tr>
<tr>
<td></td>
<td>(7.2, 2.3 to 23.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Older age</td>
<td>Ø</td>
<td>NA</td>
<td>NA</td>
<td>Ø</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past healthcare usage</td>
<td>NA</td>
<td>✓ (1.3, 1.1 to 1.5)</td>
<td>NA</td>
<td>✓ (1.47, 1.18 to 1.80)</td>
<td>Ø</td>
<td>Ø</td>
<td>NA</td>
<td>✓ (0.98, 0.97 to 1.0)</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severity</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Ø</td>
<td>Ø</td>
<td>Ø</td>
<td>NA</td>
<td>✓ (2.51, 1.12 to 5.62)</td>
<td>NA</td>
</tr>
<tr>
<td>Symptom duration</td>
<td>NA</td>
<td>✓ (2.5, 1.2 to 5.2)</td>
<td>NA</td>
<td>Ø</td>
<td>✓ (1.7, 1.3 to 2.3)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>ICS at presentation</td>
<td>✓</td>
<td>NA</td>
<td>✓ (3.1, 1.0 to 9.8)</td>
<td>NA</td>
<td>✓ (1.39, 1.07 to 1.78)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Cost/insurance</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Ø</td>
<td>Ø</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>✓ (1.15, 1.0 to 1.32)</td>
</tr>
</tbody>
</table>

ED, emergency department; ICS, inhaled corticosteroids.

Figure 4  Adjusted ORs for female sex acting as a predictor for acute asthma relapse after ED treatment and discharge. ED, emergency department.

that many studies were missed. Fourth, the ORs of non-significant factors from multivariable analyses were not reported in most papers, which may over-represent the influence of some factors. Finally, selection bias is always a concern in systematic reviews; however, two independent reviewers with a separate third-party adjudicator were used throughout all stages of the review in order to minimise selection bias and ensure consistency.

CONCLUSION
Reducing relapses after treatment for acute asthma represents a potential improvement in the quality of life for patients with asthma and a reducible strain on crowded EDs. Moreover, they present an opportunity to improve outcomes for patients while reducing direct healthcare costs. Practical factors associated with relapse occurrence within 4 weeks of ED discharge have been identified, which may help to stratify patients based on their risks and potentially influence disposition decisions. Further research should focus on strategies to decrease relapses using validated clinical decision rules in order to identify patients at high risk for relapse after discharge, optimise their management and improve outcomes.

REFERENCES


27. Sandy C. A filter to retrieve studies related to Emergency Departments from the OVID MEDLINE Database. John W. Scott Health Sciences Library, University of Alberta, 2015.


Factors associated with relapse in adult patients discharged from the emergency department following acute asthma: a systematic review
Jesse Hill, Nicholas Arrotta, Cristina Villa-Roel, Liz Dennett and Brian H Rowe

BMJ Open Resp Res 2017 4:
doi: 10.1136/bmjresp-2016-000169

Updated information and services can be found at:
http://bmjopenrespres.bmj.com/content/4/1/e000169

These include:

References
This article cites 31 articles, 3 of which you can access for free at:
http://bmjopenrespres.bmj.com/content/4/1/e000169#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/